David Scott Miller


AuthID: R-00K-250

Publications Requiring Validation

1
TITLE: Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025, SOURCE: Clinical Cancer Research
INDEXED IN: CrossRef
IN MY: ORCID
2
TITLE: Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
3
TITLE: Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
4
TITLE: Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
5
TITLE: Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
6
TITLE: Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
7
TITLE: Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
8
TITLE: Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS: Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel; David Scott Miller; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED: 2025
INDEXED IN: CrossRef
IN MY: ORCID
9
TITLE: CONTRIBUTORS
AUTHORS: SURINDER K AGGARWAL; DAVID S ALBERTS; SUSAN T ARNOLD; LAURENCE H BAKER; BARTHEL BARLOGIE; ROBERT S BENJAMIN; JOHN-PIERRE BERGERAT; RAKESH BHUTANI; WERNER C BIERBAUM; JOHN BLESSING; WILLIAM T BRADNER; HOWARD W BRUCKNER; JOSEPH H BURCHENAL; DIONISIO CALVO C III; BRENDA CAPARROS; STEPHEN K CARTER; SYLVIA CLARKE; MICHAEL J CLEARE; HUGH McD. CLINK; CARMEL J COHEN; ROBERT L COMIS; PETER CORRY; STANLEY T CROOKE; YERACH DASKAL; PHILIP DiSALA; EVAN B DOUPLE; GARY J DOYLE; BENJAMIN DREWINKO; JOHN R DURANT; LAWRENCE H EINHORN; DAVID ELSON; RONALD H ERLICH; WILLIAM E EVANS; HADRIAN N.A FRAVAL; MICHAEL A FRIEDMAN; GLEN GALE; JUDITH GOLDBERG; ALPHONSE P GRANATEK; ALEXANDER A GREEN; EZRA M GREENSPAN; ANTHONY M GUARINO; SAUL B GUSBERG; MANUEL GUTIERREZ; JONAS A GYLYS; MILES P HACKER; KENNETH R HARRAP; ANN A HAYES; DERIC R HEPBURN; MARKUS HIGI; ROBERT D HILGERS; JAMES F HOLLAND; HOWARD HOMESLEY; WAUN KI HONG; CATHRYN B HOWARTH; JAMES B HUFTALEN; PAUL C HYDES; CHARLOTTE JACOBS; MERVYN JONES; HERBERT JUERGENS; KURT W KOHN; LEO LAGASSE; LINDA LOKYS; DAVID F LONG; BERNARD W MALERBI; RANDALL C MANAKA; FRANK MANTZ; ELIO P MARIANI; PIERRE W MARTIMBEAU; NANCY MASON; STEVEN B MASTERS; GEORGES MATHÉ; GIORA M MAVLIGIT; CLAUDE MERRIN; David Scott Miller; BERNARD C.V MITCHLEY; SEYMOUR MONG; THOMAS E MOON; DESPINA MOURATIDOU; FRANCO M MUGGIA; WILLIAM M MURPHY; NORBERT NIEDERLE; ANITA NIRENBERG; ROBERT O'TOOLE; YEHUDA Z PATT; CHARLES B PRATT; ARCHIE W PRESTAYKO; RAMACHANDRAN, C; ARNOLD J REPTA; PATRICIA RIBAUD; ROBERT C RICHMOND; SAUL RIVKIN; JOHN J ROBERTS; WILLIAM C ROSE; GERALD ROSEN; BARNETT ROSENBERG; MAX E SCHEULEN; RUDOLF B SCHILCHER; CARL G SCHMIDT; JOHN E SCHURIG; SIEGFRIED SEEBER; NEIL SENZER; STANLEY M SHAPSHAY; HUGH SHINGLETON; MARK S SOLOWAY; BRUCE J SOUTHARD; STEPHEN SPARROW; RONALD L STEPHENS; STUART STRONG; CHARLOTTE TAN; TATE T THIGPEN; JOHN TURKEVICH; MARY A URBANEK; ANN VEASEY; DANIEL D VON HOFF; ROBERT C WALLACH; MICHAEL W WHITEHOUSE; RAY R WILKINSON; STEPHEN D WILLIAMS; WALTER WOLF; MARY K WOLPERT-DeFILIPPES; JOHN T WOOLEVER; ALAN YAGODA; LEONARD A ZWELLING; ...More
PUBLISHED: 1980, SOURCE: Cisplatin
INDEXED IN: CrossRef
IN MY: ORCID

footer slogan

Useful Links

Get Help

© 2025 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service